Hiroshi Hongo, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Taxoids | 9 | 2022 | 667 | 1.920 |
Why?
|
Prostatic Neoplasms | 12 | 2023 | 11106 | 0.810 |
Why?
|
Topoisomerase II Inhibitors | 1 | 2021 | 94 | 0.760 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2021 | 122 | 0.740 |
Why?
|
Fanconi Anemia Complementation Group A Protein | 1 | 2020 | 50 | 0.690 |
Why?
|
Drug Resistance, Neoplasm | 9 | 2021 | 5304 | 0.680 |
Why?
|
Antineoplastic Agents | 12 | 2021 | 13635 | 0.610 |
Why?
|
Ureteral Neoplasms | 2 | 2016 | 107 | 0.560 |
Why?
|
Epididymitis | 1 | 2016 | 37 | 0.550 |
Why?
|
Bone Neoplasms | 3 | 2022 | 2527 | 0.420 |
Why?
|
DNA Repair | 1 | 2021 | 2043 | 0.400 |
Why?
|
Prostate | 6 | 2022 | 1773 | 0.350 |
Why?
|
Adenocarcinoma | 5 | 2021 | 6340 | 0.340 |
Why?
|
Etoposide | 2 | 2021 | 634 | 0.320 |
Why?
|
Androgen Antagonists | 2 | 2019 | 1409 | 0.300 |
Why?
|
BRCA2 Protein | 3 | 2022 | 797 | 0.290 |
Why?
|
Carcinoma, Neuroendocrine | 2 | 2021 | 339 | 0.270 |
Why?
|
Quinolinium Compounds | 1 | 2006 | 10 | 0.270 |
Why?
|
Decision Support Techniques | 1 | 2016 | 1998 | 0.270 |
Why?
|
Malonates | 1 | 2006 | 43 | 0.260 |
Why?
|
Cyclohexanones | 1 | 2006 | 30 | 0.260 |
Why?
|
Pyridinium Compounds | 1 | 2006 | 81 | 0.260 |
Why?
|
Prostate-Specific Antigen | 6 | 2022 | 2465 | 0.240 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2024 | 3599 | 0.240 |
Why?
|
Transcription Factor CHOP | 1 | 2024 | 68 | 0.240 |
Why?
|
Retinoblastoma Binding Proteins | 2 | 2022 | 101 | 0.230 |
Why?
|
Activating Transcription Factor 4 | 1 | 2024 | 84 | 0.230 |
Why?
|
Nitriles | 3 | 2019 | 971 | 0.230 |
Why?
|
Cell Line, Tumor | 7 | 2024 | 16967 | 0.230 |
Why?
|
Pimozide | 1 | 2021 | 21 | 0.200 |
Why?
|
Scavenger Receptors, Class A | 1 | 2021 | 52 | 0.190 |
Why?
|
Japan | 6 | 2022 | 1372 | 0.190 |
Why?
|
Urinary Bladder Neoplasms | 3 | 2019 | 2223 | 0.190 |
Why?
|
Hypoalbuminemia | 1 | 2021 | 86 | 0.180 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 1 | 2021 | 164 | 0.180 |
Why?
|
Mice, Nude | 2 | 2024 | 3605 | 0.180 |
Why?
|
Receptors, Androgen | 3 | 2022 | 1079 | 0.180 |
Why?
|
Hyperuricemia | 1 | 2023 | 222 | 0.180 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2021 | 223 | 0.180 |
Why?
|
Castration | 1 | 2020 | 151 | 0.170 |
Why?
|
Male | 32 | 2024 | 360358 | 0.170 |
Why?
|
PTEN Phosphohydrolase | 2 | 2022 | 1113 | 0.160 |
Why?
|
Muscular Atrophy | 1 | 2022 | 334 | 0.160 |
Why?
|
Urinary Tract | 1 | 2022 | 313 | 0.160 |
Why?
|
Tissue Adhesives | 1 | 2020 | 173 | 0.160 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15828 | 0.150 |
Why?
|
Serum Albumin | 1 | 2021 | 672 | 0.150 |
Why?
|
Electron Transport Complex IV | 1 | 2018 | 190 | 0.150 |
Why?
|
Benzamides | 3 | 2019 | 1371 | 0.150 |
Why?
|
Postoperative Hemorrhage | 1 | 2021 | 414 | 0.150 |
Why?
|
Germ Cells | 1 | 2022 | 634 | 0.150 |
Why?
|
Carboplatin | 1 | 2019 | 793 | 0.130 |
Why?
|
Early Detection of Cancer | 2 | 2021 | 3196 | 0.130 |
Why?
|
Gamma Rays | 1 | 2017 | 318 | 0.130 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2018 | 614 | 0.130 |
Why?
|
Drug-Eluting Stents | 1 | 2022 | 681 | 0.130 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2022 | 1894 | 0.120 |
Why?
|
Humans | 37 | 2024 | 760617 | 0.120 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2022 | 2917 | 0.120 |
Why?
|
Quinolines | 1 | 2018 | 764 | 0.100 |
Why?
|
Nephrectomy | 2 | 2016 | 937 | 0.100 |
Why?
|
Imidazoles | 1 | 2018 | 1175 | 0.100 |
Why?
|
Neoplasm Metastasis | 2 | 2020 | 4910 | 0.100 |
Why?
|
Arachidonic Acid | 1 | 2013 | 427 | 0.100 |
Why?
|
Myocardial Infarction | 2 | 2024 | 11459 | 0.100 |
Why?
|
Sequence Analysis, DNA | 2 | 2020 | 4739 | 0.100 |
Why?
|
Ureter | 1 | 2014 | 368 | 0.100 |
Why?
|
Signal Transduction | 4 | 2024 | 23416 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2020 | 3634 | 0.090 |
Why?
|
Lung Diseases, Interstitial | 1 | 2019 | 918 | 0.090 |
Why?
|
Cell Cycle Proteins | 1 | 2021 | 3447 | 0.090 |
Why?
|
Cell Proliferation | 3 | 2023 | 10432 | 0.080 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2016 | 782 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2018 | 2456 | 0.080 |
Why?
|
Eicosapentaenoic Acid | 1 | 2013 | 561 | 0.080 |
Why?
|
Kidney Neoplasms | 2 | 2016 | 4250 | 0.080 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2015 | 612 | 0.080 |
Why?
|
Aged | 15 | 2023 | 169042 | 0.080 |
Why?
|
Headache | 1 | 2017 | 1255 | 0.080 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2018 | 2864 | 0.080 |
Why?
|
Gene Expression | 1 | 2021 | 7568 | 0.080 |
Why?
|
Middle Aged | 13 | 2023 | 220584 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2016 | 1051 | 0.080 |
Why?
|
Laparoscopy | 1 | 2020 | 2030 | 0.080 |
Why?
|
Apoptosis | 1 | 2024 | 9476 | 0.080 |
Why?
|
Cell Survival | 1 | 2018 | 5780 | 0.080 |
Why?
|
Prognosis | 5 | 2024 | 29600 | 0.080 |
Why?
|
Repressor Proteins | 1 | 2019 | 2985 | 0.080 |
Why?
|
Retrospective Studies | 9 | 2022 | 80566 | 0.080 |
Why?
|
Mice | 4 | 2024 | 81368 | 0.070 |
Why?
|
Immunohistochemistry | 1 | 2021 | 11069 | 0.070 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4571 | 0.070 |
Why?
|
Nuclear Proteins | 2 | 2019 | 5789 | 0.070 |
Why?
|
Urinary Tract Infections | 1 | 2013 | 802 | 0.070 |
Why?
|
Brain Neoplasms | 2 | 2019 | 9026 | 0.070 |
Why?
|
Macrophages | 1 | 2021 | 5758 | 0.070 |
Why?
|
Organic Chemistry Phenomena | 1 | 2006 | 4 | 0.070 |
Why?
|
Lymphatic Metastasis | 1 | 2014 | 2913 | 0.070 |
Why?
|
Chemistry, Organic | 1 | 2006 | 9 | 0.070 |
Why?
|
Biopsy | 2 | 2019 | 6762 | 0.070 |
Why?
|
Phenylthiohydantoin | 2 | 2019 | 205 | 0.070 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2014 | 3514 | 0.060 |
Why?
|
Acute Disease | 1 | 2016 | 7237 | 0.060 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 1405 | 0.060 |
Why?
|
Feasibility Studies | 1 | 2016 | 5239 | 0.060 |
Why?
|
Disease Models, Animal | 2 | 2021 | 18221 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6474 | 0.060 |
Why?
|
Lung Neoplasms | 2 | 2019 | 13382 | 0.060 |
Why?
|
Disease-Free Survival | 3 | 2022 | 6807 | 0.060 |
Why?
|
Anti-Bacterial Agents | 2 | 2021 | 7402 | 0.060 |
Why?
|
Cytokines | 1 | 2019 | 7373 | 0.060 |
Why?
|
Uricosuric Agents | 1 | 2023 | 30 | 0.060 |
Why?
|
Age Factors | 2 | 2018 | 18381 | 0.050 |
Why?
|
Hypertension | 1 | 2023 | 8529 | 0.050 |
Why?
|
Survival Analysis | 1 | 2016 | 10073 | 0.050 |
Why?
|
Treatment Outcome | 6 | 2022 | 64568 | 0.050 |
Why?
|
Animals | 4 | 2024 | 168201 | 0.050 |
Why?
|
Cisplatin | 2 | 2019 | 1650 | 0.050 |
Why?
|
Mutation | 3 | 2022 | 30016 | 0.050 |
Why?
|
Trimethylsilyl Compounds | 1 | 2002 | 8 | 0.050 |
Why?
|
Gene Expression Profiling | 1 | 2018 | 9417 | 0.050 |
Why?
|
Butadienes | 1 | 2002 | 107 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5672 | 0.050 |
Why?
|
Nuclear Respiratory Factor 1 | 1 | 2021 | 23 | 0.050 |
Why?
|
Seminal Vesicles | 1 | 2021 | 103 | 0.050 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14648 | 0.050 |
Why?
|
Aged, 80 and over | 6 | 2023 | 58894 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2019 | 4845 | 0.040 |
Why?
|
Acute Coronary Syndrome | 1 | 2013 | 2190 | 0.040 |
Why?
|
Cyanoacrylates | 1 | 2020 | 46 | 0.040 |
Why?
|
Ribavirin | 1 | 2021 | 392 | 0.040 |
Why?
|
Tumor Microenvironment | 2 | 2023 | 3868 | 0.040 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2022 | 655 | 0.040 |
Why?
|
Allelic Imbalance | 1 | 2019 | 77 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 12966 | 0.040 |
Why?
|
Quinolones | 1 | 2002 | 378 | 0.040 |
Why?
|
Risk Factors | 4 | 2024 | 74115 | 0.040 |
Why?
|
Adrenalectomy | 1 | 2020 | 346 | 0.040 |
Why?
|
Sutures | 1 | 2020 | 282 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2019 | 385 | 0.040 |
Why?
|
Sequence Deletion | 1 | 2022 | 1490 | 0.040 |
Why?
|
Homozygote | 1 | 2022 | 1776 | 0.040 |
Why?
|
Kallikreins | 1 | 2018 | 220 | 0.040 |
Why?
|
Uric Acid | 1 | 2023 | 807 | 0.040 |
Why?
|
Polysaccharides | 1 | 2023 | 1013 | 0.030 |
Why?
|
Algorithms | 1 | 2016 | 14018 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2019 | 1608 | 0.030 |
Why?
|
Androgens | 1 | 2022 | 1285 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2021 | 12043 | 0.030 |
Why?
|
Cadherins | 1 | 2019 | 901 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2019 | 737 | 0.030 |
Why?
|
Urinalysis | 1 | 2016 | 368 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2021 | 8542 | 0.030 |
Why?
|
Eleutherococcus | 1 | 2013 | 5 | 0.030 |
Why?
|
Prostatectomy | 1 | 2021 | 1824 | 0.030 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2024 | 2118 | 0.030 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2019 | 943 | 0.030 |
Why?
|
Mice, Inbred BALB C | 1 | 2021 | 6188 | 0.030 |
Why?
|
Anemia | 1 | 2021 | 1504 | 0.020 |
Why?
|
Regression Analysis | 1 | 2021 | 6338 | 0.020 |
Why?
|
Gadolinium | 1 | 2017 | 959 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2021 | 4269 | 0.020 |
Why?
|
Drugs, Chinese Herbal | 1 | 2013 | 144 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2022 | 6305 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2016 | 2495 | 0.020 |
Why?
|
Dyspnea | 1 | 2019 | 1347 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2013 | 15612 | 0.020 |
Why?
|
Smoking | 2 | 2021 | 9050 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2019 | 1852 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2019 | 3593 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2014 | 0.020 |
Why?
|
RNA-Binding Proteins | 1 | 2019 | 1890 | 0.020 |
Why?
|
Calcium Channel Blockers | 1 | 2013 | 694 | 0.020 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2022 | 2745 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2019 | 2160 | 0.020 |
Why?
|
Escherichia coli Infections | 1 | 2013 | 518 | 0.020 |
Why?
|
Risk | 1 | 2021 | 9604 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2021 | 3548 | 0.020 |
Why?
|
Antigens, CD | 1 | 2019 | 3998 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39063 | 0.020 |
Why?
|
Antibiotic Prophylaxis | 1 | 2013 | 637 | 0.020 |
Why?
|
Prospective Studies | 2 | 2023 | 54360 | 0.020 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2021 | 2249 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2018 | 2447 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2013 | 1810 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2021 | 11116 | 0.020 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2013 | 1040 | 0.020 |
Why?
|
Registries | 1 | 2021 | 8207 | 0.020 |
Why?
|
Contrast Media | 1 | 2017 | 5305 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 9277 | 0.010 |
Why?
|
Incidence | 1 | 2021 | 21337 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2021 | 5835 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2021 | 11874 | 0.010 |
Why?
|
Atrial Fibrillation | 1 | 2021 | 5031 | 0.010 |
Why?
|
Risk Assessment | 1 | 2024 | 23972 | 0.010 |
Why?
|
Phenanthridines | 1 | 2002 | 51 | 0.010 |
Why?
|
Cyclization | 1 | 2002 | 59 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2019 | 7847 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12447 | 0.010 |
Why?
|
Aspirin | 1 | 2013 | 3127 | 0.010 |
Why?
|
Coronary Angiography | 1 | 2013 | 4470 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 11736 | 0.010 |
Why?
|
Escherichia coli | 1 | 2013 | 4209 | 0.010 |
Why?
|
Stereoisomerism | 1 | 2002 | 613 | 0.010 |
Why?
|
Lung | 1 | 2019 | 9998 | 0.010 |
Why?
|
Hypoglycemic Agents | 1 | 2013 | 3085 | 0.010 |
Why?
|
Electrons | 1 | 2002 | 265 | 0.010 |
Why?
|
Female | 4 | 2023 | 392148 | 0.010 |
Why?
|
Disease Progression | 1 | 2017 | 13495 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2017 | 36402 | 0.010 |
Why?
|
Adult | 3 | 2019 | 220969 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20556 | 0.010 |
Why?
|
Neoplasms | 1 | 2021 | 22131 | 0.010 |
Why?
|
Brain | 1 | 2019 | 27101 | 0.010 |
Why?
|